MS INTERNATIONAL PLC — AGM Information 2021

Jun 14, 2021

National Storage Mechanism | Additional information

RNS Number : 8349B

SourceBio International PLC

14 June 2021

14 June 2021

SourceBio International plc

('SourceBio')

RESULT OF ANNUAL GENERAL MEETING

SourceBio confirms that all resolutions put to the 2021 Annual General Meeting held on the 14 June were

duly passed by the required majority.

Voting on the resolutions was as follows:

Resolution	Description	For	Against	Withheld
1	To receive and approve the Company's Annual Report and Accounts for the financial year ended 31 December 2020 together with the Directors' Report (including the Strategic Report) and the Auditor's Report.	58,529,422	802	400
2	To receive and approve the Directors' Remuneration Report for the financial year ended 31 December 2020, excluding the proposed remuneration policy, executive share options plan and Save As You Earn ("SAYE") scheme.	58,523,385	7,239	Nil
3	To approve the proposed remuneration policy expected to be applied in 2021.	57,772,392	8,232	750,000
4	To approve the establishment and implementation of a proposed executive share options plan.	57,767,232	8,392	755,000
5	To approve the establishment and implementation of a proposed SAYE scheme.	58,527,668	1,556	1,400
6	To re-elect Jay LeCoque (Executive Chairman) as a Director of the Company.	58,529,756	868	Nil
7	To re-elect Tony Ratcliffe (Chief Financial Officer) as a Director of the Company.	58,530,624	Nil	Nil
8	To re-elect Sir Ian Carruthers (Senior Independent Non-Executive Director) as a Director of the Company.	58,526,545	3,748	331
9	To re-elect Simon Constantine (Independent Non-Executive Director) as a Director of the Company.	58,529,091	1,533	Nil
10	To re-elect Marco Fumagalli (Non-Executive Director) as a Director of the Company.	58,529,956	668	Nil
11	To re-elect Christopher Mills (Non-Executive Director) as a Director of the Company.	58,528,891	1,733	Nil
12	To re-appoint RSM UK Audit LLP as auditor of the Company and to authorise the Directors to fix their remuneration.	58,529,024	1,600	Nil
13	To authorise the Directors generally to allot ordinary shares up to the specified limit.	58,524,551	5,673	400
14 *	To empower the Directors to issue shares free from statutory pre-emption rights up to the specified limit.	58,518,215	12,409	Nil
15 *	To authorise amendment to the Company's Articles of Association.	58,524,345	1,279	5,000

*  Special Resolution

A trading update was released at 7.00am this morning.

Notes:

·    Any proxy appointments which gave direction to the Executive Chairman have been included in the "for" column;

·    The total number of shares in issue is 74,183,038 

Contacts:

SourceBio International plc		www.sourcebiointernational.com
Jay LeCoque, Executive Chairman		Via Walbrook PR
Tony Ratcliffe, Chief Financial Officer
Liberum (Nominated Advisor and Broker)		Tel: 020 3100 2000
Bidhi Bhoma Richard Lindley
Euan Brown
Walbrook PR Limited	Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen		Mob: 07980 541 893 / 07502 558 258

About SourceBio International plc www.sourcebiointernational.com

SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four core businesses areas:

·     Infectious Disease Testing - a range of COVID-19 testing services for commercial enterprises, private healthcare groups, NHS and the DHSC.  Utilising multiple technologies, SourceBio offers screening, gold standard RT-PCR and whole genome sequencing COVID-19 testing solutions and operates under ISO 15189 accreditation required by the DHSC.  SourceBio also provides employee testing solutions to industry, direct to consumer home test kits (including 'Fit to Fly', 'Test to Release' and '2 & 8 Day International Travel' approved tests) whilst also being the lead operator on mobile testing unit services to support outbreak testing for the DHSC, event and venue testing.

·     Healthcare Diagnostics - histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.

·     Genomics - DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.

·     Stability Storage - shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA.

More details on Group operations can be found here: www.sourcebioscience.com

SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGUSVURAAUNAAR